Radiolabeling and biodistribution of new acetylcholinesterase inhibitor - 6-Hydrazino-IV-[5-(2,3-dihydro-1H-cyclopenta[b] quinolin-9-ylamino)pentyl] nicotinamide hydrochloride

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F12%3A10133990" target="_blank" >RIV/00216208:11160/12:10133990 - isvavai.cz</a>

Výsledek na webu

<a href="http://wydawnictwo.umlub.pl/pharmacy/en/artykul/szczegoly/id/3579" target="_blank" >http://wydawnictwo.umlub.pl/pharmacy/en/artykul/szczegoly/id/3579</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Radiolabeling and biodistribution of new acetylcholinesterase inhibitor - 6-Hydrazino-IV-[5-(2,3-dihydro-1H-cyclopenta[b] quinolin-9-ylamino)pentyl] nicotinamide hydrochloride

Popis výsledku v původním jazyce

Nowadays research concerning new strategies for earlier diagnosis is among the most active areas in Alzheimer's science. Brain imaging techniques are among the most promising areas of research focused on early detection of Alzheimer's disease (AD). In the present study we describe radiolabeling of a novel acetylcholinesterase inhibitor 6-hydrazino-N-[5-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylamino)pentyl]nicotinamide (5C-5) with 99m-Technetium (99mTc). Biodistribution study of compound 5C-5 radiolabeled with 99mTc after intravenous administration to rats was also performed. According to biodistribution study 99mTc-radioactivity was mainly localized in the liver, partly also in the kidney, lung and gastrointestinal tract. Furthermore, compound under study revealed comparatively rapid blood radioactivity clearance.

Název v anglickém jazyce

Radiolabeling and biodistribution of new acetylcholinesterase inhibitor - 6-Hydrazino-IV-[5-(2,3-dihydro-1H-cyclopenta[b] quinolin-9-ylamino)pentyl] nicotinamide hydrochloride

Popis výsledku anglicky

Nowadays research concerning new strategies for earlier diagnosis is among the most active areas in Alzheimer's science. Brain imaging techniques are among the most promising areas of research focused on early detection of Alzheimer's disease (AD). In the present study we describe radiolabeling of a novel acetylcholinesterase inhibitor 6-hydrazino-N-[5-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylamino)pentyl]nicotinamide (5C-5) with 99m-Technetium (99mTc). Biodistribution study of compound 5C-5 radiolabeled with 99mTc after intravenous administration to rats was also performed. According to biodistribution study 99mTc-radioactivity was mainly localized in the liver, partly also in the kidney, lung and gastrointestinal tract. Furthermore, compound under study revealed comparatively rapid blood radioactivity clearance.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

<a href="/cs/project/GAP304%2F10%2F1738" target="_blank" >GAP304/10/1738: Radioaktivně značené neuropeptidy cílené pro diagnostiku a terapii nádorů</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Annales Universitatis Mariae Curie-Sklodowska, Sectio DDD: Pharmacia

ISSN

0867-0609

e-ISSN

—

Svazek periodika

25

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

PL - Polská republika

Počet stran výsledku

5

Strana od-do

294-298

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—